Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy
Abstract Background We examined the prognostic significance of circulating tumor cell (CTC) dynamics during treatment in metastatic breast cancer (MBC) patients receiving first-line chemotherapy. Methods Serial CTC data from 469 patients (2202 samples) were used to build a novel latent mixture model...
Gespeichert in:
Veröffentlicht in: | JNCI : Journal of the National Cancer Institute 2021-04, Vol.113 (4), p.443-452 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 452 |
---|---|
container_issue | 4 |
container_start_page | 443 |
container_title | JNCI : Journal of the National Cancer Institute |
container_volume | 113 |
creator | Magbanua, Mark Jesus M Hendrix, Laura H Hyslop, Terry Barry, William T Winer, Eric P Hudis, Clifford Toppmeyer, Deborah Carey, Lisa Anne Partridge, Ann H Pierga, Jean-Yves Fehm, Tanja Vidal-Martínez, José Mavroudis, Dimitrios Garcia-Saenz, Jose A Stebbing, Justin Gazzaniga, Paola Manso, Luis Zamarchi, Rita Antelo, María Luisa Mattos-Arruda, Leticia De Generali, Daniele Caldas, Carlos Munzone, Elisabetta Dirix, Luc Delson, Amy L Burstein, Harold J Qadir, Misbah Ma, Cynthia Scott, Janet H Bidard, François-Clément Park, John W Rugo, Hope S |
description | Abstract
Background
We examined the prognostic significance of circulating tumor cell (CTC) dynamics during treatment in metastatic breast cancer (MBC) patients receiving first-line chemotherapy.
Methods
Serial CTC data from 469 patients (2202 samples) were used to build a novel latent mixture model to identify groups with similar CTC trajectory (tCTC) patterns during the course of treatment. Cox regression was used to estimate hazard ratios for progression-free survival (PFS) and overall survival (OS) in groups based on baseline CTCs, combined CTC status at baseline to the end of cycle 1, and tCTC. Akaike information criterion was used to select the model that best predicted PFS and OS.
Results
Latent mixture modeling revealed 4 distinct tCTC patterns: undetectable CTCs (56.9% ), low (23.7%), intermediate (14.5%), or high (4.9%). Patients with low, intermediate, and high tCTC patterns had statistically significant inferior PFS and OS compared with those with undetectable CTCs (P < .001). Akaike Information Criterion indicated that the tCTC model best predicted PFS and OS compared with baseline CTCs and combined CTC status at baseline to the end of cycle 1 models. Validation studies in an independent cohort of 1856 MBC patients confirmed these findings. Further validation using only a single pretreatment CTC measurement confirmed prognostic performance of the tCTC model.
Conclusions
We identified 4 novel prognostic groups in MBC based on similarities in tCTC patterns during chemotherapy. Prognostic groups included patients with very poor outcome (intermediate + high CTCs, 19.4%) who could benefit from more effective treatment. Our novel prognostic classification approach may be used for fine-tuning of CTC-based risk stratification strategies to guide future prospective clinical trials in MBC. |
doi_str_mv | 10.1093/jnci/djaa113 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8023821</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/jnci/djaa113</oup_id><sourcerecordid>2431807169</sourcerecordid><originalsourceid>FETCH-LOGICAL-c444t-b894f39baf1573f41423a5a3f0b8b7d1e02548a404090296261d65d9271490c03</originalsourceid><addsrcrecordid>eNp9kU2LFDEQhoMo7uzqzbMEPOjBdisf3UkuwtrsqjAi6HoO6XR6J0N3MibdC_PvzTDjoh6sSxXUUy9V9SL0gsA7AopdboP1l_3WGELYI7QivIGKEqgfoxUAFZWUgp-h85y3UEJR_hSdMSoEUC5WaPPdJW9GfBXMuM8-4zjg1ie7jGb24Q7fLlNMuHXjmLEP-IubTZ5Ly-IPyZUStyZYl_A3Z52_P0zc-JTnau2Dw-3GTXHeuGR2-2foyWDG7J6f8gX6cXN9236q1l8_fm6v1pXlnM9VJxUfmOrMQGrBBk44ZaY2bIBOdqInDmjNpeHAQQFVDW1I39S9ooJwBRbYBXp_1N0t3eR668KczKh3yU8m7XU0Xv_dCX6j7-K9lkCZpKQIvDkJpPhzcXnWk8-2PMAEF5esKWdEgiCNKuirf9BtXFL5ZKFqJWQNhPFCvT1SNsWckxseliGgDxbqg4X6ZGHBX_55wAP827MCvD4Ccdn9X-oX28Klrw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2597850134</pqid></control><display><type>article</type><title>Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Magbanua, Mark Jesus M ; Hendrix, Laura H ; Hyslop, Terry ; Barry, William T ; Winer, Eric P ; Hudis, Clifford ; Toppmeyer, Deborah ; Carey, Lisa Anne ; Partridge, Ann H ; Pierga, Jean-Yves ; Fehm, Tanja ; Vidal-Martínez, José ; Mavroudis, Dimitrios ; Garcia-Saenz, Jose A ; Stebbing, Justin ; Gazzaniga, Paola ; Manso, Luis ; Zamarchi, Rita ; Antelo, María Luisa ; Mattos-Arruda, Leticia De ; Generali, Daniele ; Caldas, Carlos ; Munzone, Elisabetta ; Dirix, Luc ; Delson, Amy L ; Burstein, Harold J ; Qadir, Misbah ; Ma, Cynthia ; Scott, Janet H ; Bidard, François-Clément ; Park, John W ; Rugo, Hope S</creator><creatorcontrib>Magbanua, Mark Jesus M ; Hendrix, Laura H ; Hyslop, Terry ; Barry, William T ; Winer, Eric P ; Hudis, Clifford ; Toppmeyer, Deborah ; Carey, Lisa Anne ; Partridge, Ann H ; Pierga, Jean-Yves ; Fehm, Tanja ; Vidal-Martínez, José ; Mavroudis, Dimitrios ; Garcia-Saenz, Jose A ; Stebbing, Justin ; Gazzaniga, Paola ; Manso, Luis ; Zamarchi, Rita ; Antelo, María Luisa ; Mattos-Arruda, Leticia De ; Generali, Daniele ; Caldas, Carlos ; Munzone, Elisabetta ; Dirix, Luc ; Delson, Amy L ; Burstein, Harold J ; Qadir, Misbah ; Ma, Cynthia ; Scott, Janet H ; Bidard, François-Clément ; Park, John W ; Rugo, Hope S</creatorcontrib><description>Abstract
Background
We examined the prognostic significance of circulating tumor cell (CTC) dynamics during treatment in metastatic breast cancer (MBC) patients receiving first-line chemotherapy.
Methods
Serial CTC data from 469 patients (2202 samples) were used to build a novel latent mixture model to identify groups with similar CTC trajectory (tCTC) patterns during the course of treatment. Cox regression was used to estimate hazard ratios for progression-free survival (PFS) and overall survival (OS) in groups based on baseline CTCs, combined CTC status at baseline to the end of cycle 1, and tCTC. Akaike information criterion was used to select the model that best predicted PFS and OS.
Results
Latent mixture modeling revealed 4 distinct tCTC patterns: undetectable CTCs (56.9% ), low (23.7%), intermediate (14.5%), or high (4.9%). Patients with low, intermediate, and high tCTC patterns had statistically significant inferior PFS and OS compared with those with undetectable CTCs (P < .001). Akaike Information Criterion indicated that the tCTC model best predicted PFS and OS compared with baseline CTCs and combined CTC status at baseline to the end of cycle 1 models. Validation studies in an independent cohort of 1856 MBC patients confirmed these findings. Further validation using only a single pretreatment CTC measurement confirmed prognostic performance of the tCTC model.
Conclusions
We identified 4 novel prognostic groups in MBC based on similarities in tCTC patterns during chemotherapy. Prognostic groups included patients with very poor outcome (intermediate + high CTCs, 19.4%) who could benefit from more effective treatment. Our novel prognostic classification approach may be used for fine-tuning of CTC-based risk stratification strategies to guide future prospective clinical trials in MBC.</description><identifier>ISSN: 0027-8874</identifier><identifier>EISSN: 1460-2105</identifier><identifier>DOI: 10.1093/jnci/djaa113</identifier><identifier>PMID: 32770247</identifier><language>eng</language><publisher>United States: Oxford University Press</publisher><subject>Breast cancer ; Breast Neoplasms - blood ; Breast Neoplasms - drug therapy ; Breast Neoplasms - mortality ; Breast Neoplasms - pathology ; Chemotherapy ; Clinical trials ; Criteria ; Female ; Humans ; Metastases ; Metastasis ; Neoplastic Cells, Circulating - pathology ; Patients ; Prognosis ; Progression-Free Survival ; Proportional Hazards Models ; Reproducibility of Results ; Retrospective Studies ; Statistical analysis ; Statistical methods ; Survival ; Treatment Outcome ; Tumor cells ; Tumors</subject><ispartof>JNCI : Journal of the National Cancer Institute, 2021-04, Vol.113 (4), p.443-452</ispartof><rights>The Author(s) 2020. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com 2020</rights><rights>The Author(s) 2020. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.</rights><rights>The Author(s) 2020. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c444t-b894f39baf1573f41423a5a3f0b8b7d1e02548a404090296261d65d9271490c03</citedby><cites>FETCH-LOGICAL-c444t-b894f39baf1573f41423a5a3f0b8b7d1e02548a404090296261d65d9271490c03</cites><orcidid>0000-0002-4722-4824 ; 0000-0001-7144-8791 ; 0000-0003-3371-3878 ; 0000-0003-3547-1489 ; 0000-0001-5932-8949 ; 0000-0003-2113-3593 ; 0000-0001-6710-4814 ; 0000-0001-6435-2257 ; 0000-0001-6880-0301</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,1578,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32770247$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Magbanua, Mark Jesus M</creatorcontrib><creatorcontrib>Hendrix, Laura H</creatorcontrib><creatorcontrib>Hyslop, Terry</creatorcontrib><creatorcontrib>Barry, William T</creatorcontrib><creatorcontrib>Winer, Eric P</creatorcontrib><creatorcontrib>Hudis, Clifford</creatorcontrib><creatorcontrib>Toppmeyer, Deborah</creatorcontrib><creatorcontrib>Carey, Lisa Anne</creatorcontrib><creatorcontrib>Partridge, Ann H</creatorcontrib><creatorcontrib>Pierga, Jean-Yves</creatorcontrib><creatorcontrib>Fehm, Tanja</creatorcontrib><creatorcontrib>Vidal-Martínez, José</creatorcontrib><creatorcontrib>Mavroudis, Dimitrios</creatorcontrib><creatorcontrib>Garcia-Saenz, Jose A</creatorcontrib><creatorcontrib>Stebbing, Justin</creatorcontrib><creatorcontrib>Gazzaniga, Paola</creatorcontrib><creatorcontrib>Manso, Luis</creatorcontrib><creatorcontrib>Zamarchi, Rita</creatorcontrib><creatorcontrib>Antelo, María Luisa</creatorcontrib><creatorcontrib>Mattos-Arruda, Leticia De</creatorcontrib><creatorcontrib>Generali, Daniele</creatorcontrib><creatorcontrib>Caldas, Carlos</creatorcontrib><creatorcontrib>Munzone, Elisabetta</creatorcontrib><creatorcontrib>Dirix, Luc</creatorcontrib><creatorcontrib>Delson, Amy L</creatorcontrib><creatorcontrib>Burstein, Harold J</creatorcontrib><creatorcontrib>Qadir, Misbah</creatorcontrib><creatorcontrib>Ma, Cynthia</creatorcontrib><creatorcontrib>Scott, Janet H</creatorcontrib><creatorcontrib>Bidard, François-Clément</creatorcontrib><creatorcontrib>Park, John W</creatorcontrib><creatorcontrib>Rugo, Hope S</creatorcontrib><title>Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy</title><title>JNCI : Journal of the National Cancer Institute</title><addtitle>J Natl Cancer Inst</addtitle><description>Abstract
Background
We examined the prognostic significance of circulating tumor cell (CTC) dynamics during treatment in metastatic breast cancer (MBC) patients receiving first-line chemotherapy.
Methods
Serial CTC data from 469 patients (2202 samples) were used to build a novel latent mixture model to identify groups with similar CTC trajectory (tCTC) patterns during the course of treatment. Cox regression was used to estimate hazard ratios for progression-free survival (PFS) and overall survival (OS) in groups based on baseline CTCs, combined CTC status at baseline to the end of cycle 1, and tCTC. Akaike information criterion was used to select the model that best predicted PFS and OS.
Results
Latent mixture modeling revealed 4 distinct tCTC patterns: undetectable CTCs (56.9% ), low (23.7%), intermediate (14.5%), or high (4.9%). Patients with low, intermediate, and high tCTC patterns had statistically significant inferior PFS and OS compared with those with undetectable CTCs (P < .001). Akaike Information Criterion indicated that the tCTC model best predicted PFS and OS compared with baseline CTCs and combined CTC status at baseline to the end of cycle 1 models. Validation studies in an independent cohort of 1856 MBC patients confirmed these findings. Further validation using only a single pretreatment CTC measurement confirmed prognostic performance of the tCTC model.
Conclusions
We identified 4 novel prognostic groups in MBC based on similarities in tCTC patterns during chemotherapy. Prognostic groups included patients with very poor outcome (intermediate + high CTCs, 19.4%) who could benefit from more effective treatment. Our novel prognostic classification approach may be used for fine-tuning of CTC-based risk stratification strategies to guide future prospective clinical trials in MBC.</description><subject>Breast cancer</subject><subject>Breast Neoplasms - blood</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Breast Neoplasms - mortality</subject><subject>Breast Neoplasms - pathology</subject><subject>Chemotherapy</subject><subject>Clinical trials</subject><subject>Criteria</subject><subject>Female</subject><subject>Humans</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Neoplastic Cells, Circulating - pathology</subject><subject>Patients</subject><subject>Prognosis</subject><subject>Progression-Free Survival</subject><subject>Proportional Hazards Models</subject><subject>Reproducibility of Results</subject><subject>Retrospective Studies</subject><subject>Statistical analysis</subject><subject>Statistical methods</subject><subject>Survival</subject><subject>Treatment Outcome</subject><subject>Tumor cells</subject><subject>Tumors</subject><issn>0027-8874</issn><issn>1460-2105</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU2LFDEQhoMo7uzqzbMEPOjBdisf3UkuwtrsqjAi6HoO6XR6J0N3MibdC_PvzTDjoh6sSxXUUy9V9SL0gsA7AopdboP1l_3WGELYI7QivIGKEqgfoxUAFZWUgp-h85y3UEJR_hSdMSoEUC5WaPPdJW9GfBXMuM8-4zjg1ie7jGb24Q7fLlNMuHXjmLEP-IubTZ5Ly-IPyZUStyZYl_A3Z52_P0zc-JTnau2Dw-3GTXHeuGR2-2foyWDG7J6f8gX6cXN9236q1l8_fm6v1pXlnM9VJxUfmOrMQGrBBk44ZaY2bIBOdqInDmjNpeHAQQFVDW1I39S9ooJwBRbYBXp_1N0t3eR668KczKh3yU8m7XU0Xv_dCX6j7-K9lkCZpKQIvDkJpPhzcXnWk8-2PMAEF5esKWdEgiCNKuirf9BtXFL5ZKFqJWQNhPFCvT1SNsWckxseliGgDxbqg4X6ZGHBX_55wAP827MCvD4Ccdn9X-oX28Klrw</recordid><startdate>20210406</startdate><enddate>20210406</enddate><creator>Magbanua, Mark Jesus M</creator><creator>Hendrix, Laura H</creator><creator>Hyslop, Terry</creator><creator>Barry, William T</creator><creator>Winer, Eric P</creator><creator>Hudis, Clifford</creator><creator>Toppmeyer, Deborah</creator><creator>Carey, Lisa Anne</creator><creator>Partridge, Ann H</creator><creator>Pierga, Jean-Yves</creator><creator>Fehm, Tanja</creator><creator>Vidal-Martínez, José</creator><creator>Mavroudis, Dimitrios</creator><creator>Garcia-Saenz, Jose A</creator><creator>Stebbing, Justin</creator><creator>Gazzaniga, Paola</creator><creator>Manso, Luis</creator><creator>Zamarchi, Rita</creator><creator>Antelo, María Luisa</creator><creator>Mattos-Arruda, Leticia De</creator><creator>Generali, Daniele</creator><creator>Caldas, Carlos</creator><creator>Munzone, Elisabetta</creator><creator>Dirix, Luc</creator><creator>Delson, Amy L</creator><creator>Burstein, Harold J</creator><creator>Qadir, Misbah</creator><creator>Ma, Cynthia</creator><creator>Scott, Janet H</creator><creator>Bidard, François-Clément</creator><creator>Park, John W</creator><creator>Rugo, Hope S</creator><general>Oxford University Press</general><general>Oxford Publishing Limited (England)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>7U7</scope><scope>7U9</scope><scope>C1K</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-4722-4824</orcidid><orcidid>https://orcid.org/0000-0001-7144-8791</orcidid><orcidid>https://orcid.org/0000-0003-3371-3878</orcidid><orcidid>https://orcid.org/0000-0003-3547-1489</orcidid><orcidid>https://orcid.org/0000-0001-5932-8949</orcidid><orcidid>https://orcid.org/0000-0003-2113-3593</orcidid><orcidid>https://orcid.org/0000-0001-6710-4814</orcidid><orcidid>https://orcid.org/0000-0001-6435-2257</orcidid><orcidid>https://orcid.org/0000-0001-6880-0301</orcidid></search><sort><creationdate>20210406</creationdate><title>Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy</title><author>Magbanua, Mark Jesus M ; Hendrix, Laura H ; Hyslop, Terry ; Barry, William T ; Winer, Eric P ; Hudis, Clifford ; Toppmeyer, Deborah ; Carey, Lisa Anne ; Partridge, Ann H ; Pierga, Jean-Yves ; Fehm, Tanja ; Vidal-Martínez, José ; Mavroudis, Dimitrios ; Garcia-Saenz, Jose A ; Stebbing, Justin ; Gazzaniga, Paola ; Manso, Luis ; Zamarchi, Rita ; Antelo, María Luisa ; Mattos-Arruda, Leticia De ; Generali, Daniele ; Caldas, Carlos ; Munzone, Elisabetta ; Dirix, Luc ; Delson, Amy L ; Burstein, Harold J ; Qadir, Misbah ; Ma, Cynthia ; Scott, Janet H ; Bidard, François-Clément ; Park, John W ; Rugo, Hope S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c444t-b894f39baf1573f41423a5a3f0b8b7d1e02548a404090296261d65d9271490c03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Breast cancer</topic><topic>Breast Neoplasms - blood</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Breast Neoplasms - mortality</topic><topic>Breast Neoplasms - pathology</topic><topic>Chemotherapy</topic><topic>Clinical trials</topic><topic>Criteria</topic><topic>Female</topic><topic>Humans</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Neoplastic Cells, Circulating - pathology</topic><topic>Patients</topic><topic>Prognosis</topic><topic>Progression-Free Survival</topic><topic>Proportional Hazards Models</topic><topic>Reproducibility of Results</topic><topic>Retrospective Studies</topic><topic>Statistical analysis</topic><topic>Statistical methods</topic><topic>Survival</topic><topic>Treatment Outcome</topic><topic>Tumor cells</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Magbanua, Mark Jesus M</creatorcontrib><creatorcontrib>Hendrix, Laura H</creatorcontrib><creatorcontrib>Hyslop, Terry</creatorcontrib><creatorcontrib>Barry, William T</creatorcontrib><creatorcontrib>Winer, Eric P</creatorcontrib><creatorcontrib>Hudis, Clifford</creatorcontrib><creatorcontrib>Toppmeyer, Deborah</creatorcontrib><creatorcontrib>Carey, Lisa Anne</creatorcontrib><creatorcontrib>Partridge, Ann H</creatorcontrib><creatorcontrib>Pierga, Jean-Yves</creatorcontrib><creatorcontrib>Fehm, Tanja</creatorcontrib><creatorcontrib>Vidal-Martínez, José</creatorcontrib><creatorcontrib>Mavroudis, Dimitrios</creatorcontrib><creatorcontrib>Garcia-Saenz, Jose A</creatorcontrib><creatorcontrib>Stebbing, Justin</creatorcontrib><creatorcontrib>Gazzaniga, Paola</creatorcontrib><creatorcontrib>Manso, Luis</creatorcontrib><creatorcontrib>Zamarchi, Rita</creatorcontrib><creatorcontrib>Antelo, María Luisa</creatorcontrib><creatorcontrib>Mattos-Arruda, Leticia De</creatorcontrib><creatorcontrib>Generali, Daniele</creatorcontrib><creatorcontrib>Caldas, Carlos</creatorcontrib><creatorcontrib>Munzone, Elisabetta</creatorcontrib><creatorcontrib>Dirix, Luc</creatorcontrib><creatorcontrib>Delson, Amy L</creatorcontrib><creatorcontrib>Burstein, Harold J</creatorcontrib><creatorcontrib>Qadir, Misbah</creatorcontrib><creatorcontrib>Ma, Cynthia</creatorcontrib><creatorcontrib>Scott, Janet H</creatorcontrib><creatorcontrib>Bidard, François-Clément</creatorcontrib><creatorcontrib>Park, John W</creatorcontrib><creatorcontrib>Rugo, Hope S</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>JNCI : Journal of the National Cancer Institute</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Magbanua, Mark Jesus M</au><au>Hendrix, Laura H</au><au>Hyslop, Terry</au><au>Barry, William T</au><au>Winer, Eric P</au><au>Hudis, Clifford</au><au>Toppmeyer, Deborah</au><au>Carey, Lisa Anne</au><au>Partridge, Ann H</au><au>Pierga, Jean-Yves</au><au>Fehm, Tanja</au><au>Vidal-Martínez, José</au><au>Mavroudis, Dimitrios</au><au>Garcia-Saenz, Jose A</au><au>Stebbing, Justin</au><au>Gazzaniga, Paola</au><au>Manso, Luis</au><au>Zamarchi, Rita</au><au>Antelo, María Luisa</au><au>Mattos-Arruda, Leticia De</au><au>Generali, Daniele</au><au>Caldas, Carlos</au><au>Munzone, Elisabetta</au><au>Dirix, Luc</au><au>Delson, Amy L</au><au>Burstein, Harold J</au><au>Qadir, Misbah</au><au>Ma, Cynthia</au><au>Scott, Janet H</au><au>Bidard, François-Clément</au><au>Park, John W</au><au>Rugo, Hope S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy</atitle><jtitle>JNCI : Journal of the National Cancer Institute</jtitle><addtitle>J Natl Cancer Inst</addtitle><date>2021-04-06</date><risdate>2021</risdate><volume>113</volume><issue>4</issue><spage>443</spage><epage>452</epage><pages>443-452</pages><issn>0027-8874</issn><eissn>1460-2105</eissn><abstract>Abstract
Background
We examined the prognostic significance of circulating tumor cell (CTC) dynamics during treatment in metastatic breast cancer (MBC) patients receiving first-line chemotherapy.
Methods
Serial CTC data from 469 patients (2202 samples) were used to build a novel latent mixture model to identify groups with similar CTC trajectory (tCTC) patterns during the course of treatment. Cox regression was used to estimate hazard ratios for progression-free survival (PFS) and overall survival (OS) in groups based on baseline CTCs, combined CTC status at baseline to the end of cycle 1, and tCTC. Akaike information criterion was used to select the model that best predicted PFS and OS.
Results
Latent mixture modeling revealed 4 distinct tCTC patterns: undetectable CTCs (56.9% ), low (23.7%), intermediate (14.5%), or high (4.9%). Patients with low, intermediate, and high tCTC patterns had statistically significant inferior PFS and OS compared with those with undetectable CTCs (P < .001). Akaike Information Criterion indicated that the tCTC model best predicted PFS and OS compared with baseline CTCs and combined CTC status at baseline to the end of cycle 1 models. Validation studies in an independent cohort of 1856 MBC patients confirmed these findings. Further validation using only a single pretreatment CTC measurement confirmed prognostic performance of the tCTC model.
Conclusions
We identified 4 novel prognostic groups in MBC based on similarities in tCTC patterns during chemotherapy. Prognostic groups included patients with very poor outcome (intermediate + high CTCs, 19.4%) who could benefit from more effective treatment. Our novel prognostic classification approach may be used for fine-tuning of CTC-based risk stratification strategies to guide future prospective clinical trials in MBC.</abstract><cop>United States</cop><pub>Oxford University Press</pub><pmid>32770247</pmid><doi>10.1093/jnci/djaa113</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-4722-4824</orcidid><orcidid>https://orcid.org/0000-0001-7144-8791</orcidid><orcidid>https://orcid.org/0000-0003-3371-3878</orcidid><orcidid>https://orcid.org/0000-0003-3547-1489</orcidid><orcidid>https://orcid.org/0000-0001-5932-8949</orcidid><orcidid>https://orcid.org/0000-0003-2113-3593</orcidid><orcidid>https://orcid.org/0000-0001-6710-4814</orcidid><orcidid>https://orcid.org/0000-0001-6435-2257</orcidid><orcidid>https://orcid.org/0000-0001-6880-0301</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0027-8874 |
ispartof | JNCI : Journal of the National Cancer Institute, 2021-04, Vol.113 (4), p.443-452 |
issn | 0027-8874 1460-2105 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8023821 |
source | Oxford University Press Journals All Titles (1996-Current); MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
subjects | Breast cancer Breast Neoplasms - blood Breast Neoplasms - drug therapy Breast Neoplasms - mortality Breast Neoplasms - pathology Chemotherapy Clinical trials Criteria Female Humans Metastases Metastasis Neoplastic Cells, Circulating - pathology Patients Prognosis Progression-Free Survival Proportional Hazards Models Reproducibility of Results Retrospective Studies Statistical analysis Statistical methods Survival Treatment Outcome Tumor cells Tumors |
title | Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T04%3A35%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Serial%20Analysis%20of%20Circulating%20Tumor%20Cells%20in%20Metastatic%20Breast%20Cancer%20Receiving%20First-Line%20Chemotherapy&rft.jtitle=JNCI%20:%20Journal%20of%20the%20National%20Cancer%20Institute&rft.au=Magbanua,%20Mark%20Jesus%20M&rft.date=2021-04-06&rft.volume=113&rft.issue=4&rft.spage=443&rft.epage=452&rft.pages=443-452&rft.issn=0027-8874&rft.eissn=1460-2105&rft_id=info:doi/10.1093/jnci/djaa113&rft_dat=%3Cproquest_pubme%3E2431807169%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2597850134&rft_id=info:pmid/32770247&rft_oup_id=10.1093/jnci/djaa113&rfr_iscdi=true |